Variants in the SREBF2 gene can influence the effectiveness of statins like atorvastatin, used to reduce cholesterol levels, by altering how the gene regulates cholesterol synthesis. This can lead to variations in the drug's lipid-lowering efficacy and the likelihood of side effects such as myopathy.